



Fig 2 The possible mechanisms for CART combined with blinatumomab (A) Illustration of the course of treatment. (B) The assumed mechanisms of recruit CAR-T cells through scFv as an adaptor (C) binding different antigen epitopes beyond conventional surface antigens